Lexicon Pharmaceuticals backs Type 1 diabetes research ahead of World Diabetes Day

Lexicon Pharmaceuticals backs Type 1 diabetes research ahead of World Diabetes Day
@LexPharma: Lexicon backs diabetes research

Lexicon Pharmaceuticals recently expressed its support for the Type 1 diabetes community by attending the Breakthrough T1D Promise Gala in New York City. The event, which took place just ahead of World Diabetes Day, is part of the company's ongoing commitment to improving the lives of those affected by Type 1 diabetes.

By actively participating in such crucial events and supporting initiatives that aim to advance diabetes research, Lexicon Pharmaceuticals underscores its dedication to making a tangible impact on the community. The gala served as a significant platform for gathering community leaders and stakeholders committed to diabetes awareness and innovation.

Lexicon's engagement at the Promise Gala builds on its broader commitment to therapeutic innovation, aligning with its recent presentation of groundbreaking data on its cardiovascular SGLT1/2 inhibitor. As highlighted in the company’s unveiling of new insights into SGLT1/2 inhibitors, such efforts reflect a strategic focus on advancing both diabetes and cardiovascular research.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.